All Trials

Phase I/IB Study of Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent high-grade uterine/endometrial cancers (FIGO grade 3 endometrioid, serous, mixed high-grade, or carcinosarcoma) after platinum, ECOG 0–2, measurable disease, and prior HER2- or immune-therapy as appropriate, receive paclitaxel plus zanzalintinib (XL092), an oral multi-targeted TKI inhibiting VEGFR2, MET, and TAM kinases, with maintenance zanzalintinib for responders/stable disease. Excludes prior TKIs/bevacizumab, uncontrolled CV disease, high-risk bleeding/GI conditions, and untreated/unstable CNS disease.

ClinicalTrials.gov ID: NCT06795009

ENERGIZE: Engagement With a Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu: A Single-Center Pilot Study

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic breast cancer on ongoing fam-trastuzumab deruxtecan (Enhertu) after 3–4 cycles and experiencing clinician-identified fatigue are randomized to a 12-week, home-based aerobic plus resistance exercise program versus usual care. Enhertu, an anti-HER2 antibody–drug conjugate delivering a topoisomerase I inhibitor to HER2-expressing cells, continues per standard care; the study tests whether structured exercise reduces cancer-related fatigue.

ClinicalTrials.gov ID: NCT07203378

A Phase Ia/Ib Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Patients With Locally Advanced Or Metastatic ER-Positive, HER2-Negative Breast Cancer Who Have Previously Progressed During or After CDK4/6 Inhibitor Therapy

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For adults with locally advanced/metastatic ER-positive, HER2-negative breast cancer with RECIST-evaluable disease and ECOG 0–1 who progressed during/after prior CDK4/6 inhibitor therapy (no visceral crisis requiring urgent chemotherapy), this study tests oral GDC-0587, an investigational selective CDK4 inhibitor, as monotherapy or combined with giredestrant, an oral selective estrogen receptor degrader. Key aims are to define safety/PK and recommended doses, with a cohort assessing food and proton pump inhibitor (omeprazole) effects on GDC-0587 exposure.

ClinicalTrials.gov ID: NCT07214662

A Phase 1b, Open-Label Parallel Study Evaluating CLR 125 in Patients With Relapsed or Refractory Triple Negative Breast Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with measurable relapsed/refractory triple-negative breast cancer (ER/PR <10%, HER2–) after at least one prior standard regimen (including chemo/immunotherapy and ADCs as applicable), ECOG 0–2; stable treated brain metastases allowed. Patients receive IV CLR 125, an iodine-125–labeled phospholipid ether tumor-targeted radiotherapeutic that accumulates in tumor membranes to deliver short-range Auger-electron radiation, given as 4 fractionated doses per 8-week cycle with dose-level cohorts; an optional sub-study gives a single imaging dose of iopofosine I-131 (CLR 131) for dosimetry.

ClinicalTrials.gov ID: NCT07311993

A Phase 1b/2 Trial Investigating the Safety and Efficacy of Oral AMXT 1501 and Oral DFMO in Combination With Standard of Care in Patients With Advanced Solid Tumors Who Progressed After Prior Therapies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For adults with ECOG 0–1 and measurable unresectable/metastatic disease, this study enrolls either ER+/HER2− breast cancer with actionable PIK3CA/AKT1/PTEN alterations after progression on ≥2 endocrine-based regimens (candidate for fulvestrant + capivasertib) or cutaneous melanoma progressing after prior immune checkpoint inhibitor therapy (and after/intolerant to BRAF/MEK inhibitors if BRAF V600–mutant). Patients receive dual polyamine blockade with oral AMXT 1501 (polyamine transport inhibitor) plus oral DFMO/eflornithine (irreversible ornithine decarboxylase inhibitor) added to standard therapy—fulvestrant + capivasertib in breast cancer or pembrolizumab in melanoma.

ClinicalTrials.gov ID: NCT07287917

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with previously untreated locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ECOG 0–1) and measurable disease. Patients receive pembrolizumab plus mFOLFOX6 (control) or pembrolizumab combined with an antibody–drug conjugate: ifinatamab deruxtecan (B7-H3/CD276–targeted ADC delivering a cleavable topoisomerase I inhibitor payload [DXd]) with or without fluoropyrimidine/leucovorin ± oxaliplatin, or sacituzumab tirumotecan (TROP2-directed ADC with a topoisomerase I inhibitor payload) plus fluoropyrimidine/leucovorin.

ClinicalTrials.gov ID: NCT06780111

A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-711 as a Monotherapy or in Combination With Budigalimab (ABBV-181) in Adult Subjects With Advanced Squamous Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with advanced/metastatic squamous malignancies (including squamous NSCLC and head and neck SCC) that have progressed after or are not candidates for standard therapies, with measurable disease; prior PD-1/PD-L1 therapy is allowed and tumor tissue/biopsies are required for biomarker analyses in some cohorts. Patients receive oral ABBV-711 (mechanism/target not publicly disclosed) as monotherapy or in combination with budigalimab (ABBV-181), an engineered anti–PD-1 IgG1 monoclonal antibody.

ClinicalTrials.gov ID: NCT07241039

A Phase I Study of Zanzalintinib With Pembrolizumab and Cetuximab in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with incurable recurrent/metastatic head and neck squamous cell carcinoma (ECOG 0–1, measurable disease), including previously untreated R/M disease only if PD-L1 CPS ≥1 or patients previously treated with anti–PD-(L)1 therapy (no PD-L1 restriction), excluding prior EGFR inhibitors/cetuximab or VEGFR-targeted therapy and >2 prior systemic lines in the R/M setting. Patients receive oral zanzalintinib (investigational multi-kinase TKI targeting VEGFR2, MET, and TAM kinases) daily plus pembrolizumab (anti–PD-1) and cetuximab (anti-EGFR) IV in 42-day cycles with dose escalation/expansion to define the RP2D.

ClinicalTrials.gov ID: NCT06912087

A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults (ECOG 0–1) with unresectable/metastatic colorectal adenocarcinoma or metastatic castration-resistant prostate cancer. Tests the B7-H3–targeted antibody-drug conjugate GSK5764227 (anti–B7-H3 mAb linked to a topoisomerase inhibitor payload) in combination with bevacizumab ± 5-FU/leucovorin for metastatic CRC, or with enzalutamide for mCRPC.

ClinicalTrials.gov ID: NCT07277270

A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic NSCLC harboring KRAS G12C (ECOG 0–1) who have progressed on or are intolerant to platinum chemotherapy and PD-(L)1 therapy (no prior KRAS inhibitor; no other actionable driver alterations; stable/asymptomatic treated brain metastases allowed). Patients receive IV amivantamab (EGFR/MET bispecific antibody) in combination with oral olomorasib/LY3537982 (selective KRAS G12C inhibitor binding the GDP-bound mutant) until progression or unacceptable toxicity.

ClinicalTrials.gov ID: NCT07227025